

**Third IPNA-ESPN Master for Junior Classes**  
Leuven (Belgium), October 28-30<sup>th</sup>, 2016

# ***AKI PATHOGENESIS***

**Stefano Picca, MD**

**Department of Pediatrics, Dialysis Unit**

**“Bambino Gesù” Pediatric Research Hospital, IRCCS  
ROMA, Italy**







Bambino Gesù  
OSPEDALE PEDIATRICO







# *OUTLINE*

1. The scenario: **AKI in the pediatric setting**
2. AKI genesis: **causes and mechanisms**

## Pediatric AKI studies


- ***Pre-2004***: focus on RRT-requiring AKI and technique
- ***Epidemiology***: Rare, HUS, GN, sepsis, cancer
- ***Transition of PD/HD to CRRT***: prospective pediatric CRRT registry largest child Epi study
- **Post 2005:**
- Definitions
- AKI as a contributor to poor outcome
- Interest: understanding disease *patterns* and *prevention*

# *AKI in children: the dimension of the problem*


- 10% of all children admitted in PICU suffer from varying degrees of AKI (Schneider, 2010)
- AKI carries a 50% mortality rate in children requiring CRRT (Symons, 2007)
- Pediatric AKI survivors are at risk for progression to CKD (Askenazi, 2006)
- AKI worsens mortality rates, increases duration of mechanical ventilation, prolongs hospital stays in critically ill children (Basu, 2011)
- AKI-associated mortality is not solely secondary to standard sequelae (e.g., hyperkalemia, acidosis, or uremia (cross-talk between the kidney and other vital organs) (Doi, 2011)

# FACTORS AFFECTING AKI INCIDENCE

*AKI definition: more than 30 definitions until sCreat/UO based classifications...*



# AKI OR AKI RECOGNITION IS INCREASING





|  | Children<br>(n=1643)* | Adults<br>(n=993)† |
|--|-----------------------|--------------------|
| Infection  | 380 (23%)             | 274 (28%)          |
| Septicaemia  | 370                   | 232                |
| HIV  | 6                     | 0                  |
| Tetanus  | 4                     | 1                  |
| Pyelonephritis   | 0                     | 12                 |
| Typhoid  | 0                     | 7                  |
| Cholera  | 0                     | 22                 |
| Glomerular disease                                     | 350 (21%)             | 76 (8%)            |
| Acute glomerulonephritis                               | 183                   | 57                 |
| Nephrotic syndrome                                     | 115                   | 10                 |
| Rapidly progressive acute glomerulonephritis           | 46                    | 4                  |
| Lupus nephritis  | 5                     | 5                  |
| Membranoproliferative acute glomerulonephritis         | 1                     | 0                  |
| Nephrotoxin  | 270 (16%)             | 182 (18%)          |
| Haemoglobinuria from:                                  |                       |                    |
| <i>Plasmodium falciparum</i> malaria haemolysis        | 198                   | 34                 |
| G6PD deficiency haemolysis                             | 18                    | 0                  |
| Infection  | 0                     | 41                 |
| Transfusion reaction                                   | 0                     | 2                  |
| Autoimmune haemolytic anaemia                          | 2                     | 0                  |
| Herbal remedies ingestion                              | 6                     | 8                  |
| Holy water   | 0                     | 7                  |
| Henna (para-phenylenediamine)                          | 0                     | 12                 |
| Unspecified drugs                                      | 0                     | 17                 |
| Furosemide   | 5                     | 0                  |
| ACE inhibitors   | 5                     | 0                  |
| Cytotoxic drugs  | 5                     | 0                  |
| Unspecified  | 31                    | 61                 |
| Intravascular volume depletion or hypoperfusion        | 174 (11%)             | 50 (5%)            |
| Gastroenteritis  | 169                   | 42                 |
| Inadequate volume replacement before and after surgery | 4                     | 0                  |
| Severe haemorrhage                                     | 1                     | 0                  |
| Unspecified  | 0                     | 8                  |
| Obstructive uropathy                                   | 146 (9%)              | 46 (5%)            |
| Renal stone  | 60                    | 16                 |

(Table 2 continues in next column)

|  | Children<br>(n=1643)* | Adults<br>(n=993)† |
|--|-----------------------|--------------------|
| (Continued from previous column)                       |                       |                    |
| Congenital anomaly of the kidney and the urinary tract |                       |                    |
| Posterior urethral valves                              | 32                    | 0                  |
| Renal agenesis   | 4                     | 0                  |
| Prune belly syndrome                                   | 1                     | 0                  |
| Prostate   | 0                     | 9                  |
| Malignancy   | 0                     | 2                  |
| Schistosoma  | 0                     | 2                  |
| Unspecified  | 49                    | 17                 |
| Vascular disease or haemolysis                         | 116 (7%)              | 11 (1%)            |
| Haemolytic uraemic syndrome                            | 111                   | 1                  |
| Thrombotic thrombocytopenic purpura                    | 2                     | 0                  |
| Purpura fulminans                                      | 1                     | 0                  |
| Renal vein thrombosis                                  | 1                     | 1                  |
| Sickle cell crisis                                     | 1                     | 0                  |
| Haemolysis, other                                      | 0                     | 9                  |
| Medical, other   | 0                     | 36 (4%)            |
| Liver disease  | 0                     | 15                 |
| Cardiac  | 0                     | 8                  |
| Malignant hypertension                                 | 0                     | 13                 |
| Malignancy   | 40 (2%)               | 19 (2%)            |
| Birth asphyxia   | 27 (2%)               | 0                  |
| Obstetric or gynaecological                            | 0                     | 157 (16%)          |
| Septic abortion  | 0                     | 66                 |
| Pre-eclampsia or eclampsia                             | 0                     | 43                 |
| Pre-partum or post-partum haemorrhage                  | 0                     | 30                 |
| Ureter ligation after hysterectomy                     | 0                     | 7                  |
| Unspecified  | 0                     | 11                 |
| Surgical   | 0                     | 54 (5%)            |
| Trauma, burns, or fractures                            | 0                     | 43                 |
| Postoperative  | 0                     | 1                  |
| Other  | 0                     | 10                 |
| Unspecified  | 140 (9%)              | 88 (9%)            |

G6PD=glucose-6-phosphate dehydrogenase. ACE=angiotensin converting enzyme.  
\*17 paediatric studies. †14 adult studies.

**Table 2: Causes of acute kidney injury in children and adults**

kidney injury to be 72·8% and 82·9%.<sup>14,16</sup> In the remaining studies, most cases were probably community-acquired.

**Table 1** Etiology of pediatric acute renal failure (ARF)<sup>a</sup>

| Cause                                  | <i>n</i> | %    |
|--|----------|------|
| Hemolytic-uremic syndrome              | 108      | 21.0 |
| Glomerulonephritis                     | 65       | 12.6 |
| Acute tubular necrosis <sup>b</sup>    | 120      | 23.3 |
| “Intrinsic renal disease” <sup>b</sup> | 44       | 8.5  |
| Urinary obstruction                    | 17       | 3.3  |
| Postoperative                          | 35       | 6.8  |
| Sepsis                                 | 32       | 6.2  |
| Ischemic/Prerenal                      | 23       | 4.5  |
| Other <sup>c</sup>                     | 71       | 13.8 |
| Total                                  | 515      | 100  |

<sup>a</sup> Compiled from references [15, 16, 17, 18, 20, 22, 26]

<sup>b</sup> Specific causes not specified

<sup>c</sup> Including metabolic disorders, renal venous thrombosis, hepato-renal syndrome, complications of organ transplantation, and other miscellaneous causes

**1985-1997**

from Flynn JT, 2002

**Table 2. ARF Causes for Patients With Underlying Systemic Disease**


| Underlying Systemic Disease    | Most Common Primary ARF Causes                        |
|--------------------------------|---|
| Cardiac (n = 43)               | Ischemic (69%)<br>Nephrotoxins (7%)<br>Sepsis (7%)    |
| Hematology/oncology (n = 33)   | Nephrotoxins (33%)<br>Malignancy (24%)<br>Sepsis (9%) |
| Gastrointestinal (n = 11)      | Ischemic (45%)<br>Nephrotoxins (27%)                  |
| Any systemic disease (n = 187) | Ischemic (27%)<br>Nephrotoxins (18%)<br>Sepsis (9%)   |

...Primary renal diseases accounted for only 17 cases (7%; acute glomerulonephritis [9 patients], pyelonephritis [5 patients], and hemolytic uremic syndrome [3 patients]).

# ***AKI: Pediatric Issues***


- 1. Broadening of pediatric AKI epidemiology***  
due to morbidity deriving from new complex treatments  
(heart surgery, BMT, liver and heart tx, etc)

***More critical children with AKI receiving  
Intensive Care***



- 2. In critical children with AKI:***
  - Lack of prospective studies***
  - Lack of treatment stratification (medical and dialysis)***
  - Inconsistent control of illness severity***

***Outcome interpretation is difficult***






# ***PEDIATRIC MODS: EARLIER AND WORST***

*Differently from adult patients:*

- Children die less but develop MODS early in ICU course
  - Maximum number of organ failures occurs within 72 hours of ICU admission (87% of patients)
- Children die with MODS very early in ICU course
  - 88.4% of deaths occur within 7 days of MOSF diagnosis

***Quick identification of children at risk of AKI  
is needed in order to initiate early treatment***



- *How “new” pediatric AKI epidemiology affects management*
- Presently, in a typical western world, tertiary care hospital setting pediatric AKI is more often due to systemic diseases or is part of the comorbidities induced by the new treatments than to primary renal diseases.

### ***TAKE HOME MESSAGE:***

**→ we are more and more engaged in domains different from Pediatric Nephrology**

# The “classic” approach

**Table 1** Etiology of common causes of acute kidney injury

| Type                    | Etiology  |
|-------------------------|---|
| Pre-renal injury        | Decreased true intravascular volume<br>Decreased effective intravascular volume   |
| Intrinsic renal disease | Acute tubular necrosis (vasomotor nephropathy)<br>Hypoxic/ischemic insults<br>Drug induced<br>Toxin mediated<br>Endogenous toxins—hemoglobin, myoglobin<br>Exogenous toxins—ethylene glycol, methanol<br>Uric acid nephropathy and tumor lysis syndrome<br>Interstitial nephritis<br>Drug induced<br>Idiopathic<br>Glomerulonephritis—RPGN<br>Vascular lesions<br>Renal artery thrombosis<br>Renal vein thrombosis<br>Cortical necrosis<br>Hemolytic uremic syndrome<br>Hypoplasia/dysplasia with or without obstructive uropathy<br>Idiopathic<br>Exposure to nephrotoxic drugs in utero |
| Obstructive uropathy    | Obstruction in a solitary kidney<br>Bilateral ureteral obstruction<br>Urethral obstruction  |

**Table 6 | Causes of AKI: exposures and susceptibilities for non-specific AKI**

| Exposures                             | Susceptibilities                      |
|---------------------------------------|---------------------------------------|
| Sepsis                                | Dehydration or volume depletion       |
| Critical illness                      | Advanced age                          |
| Circulatory shock                     | Female gender                         |
| Burns                                 | Black race                            |
| Trauma                                | CKD                                   |
| Cardiac surgery (especially with CPB) | Chronic diseases (heart, lung, liver) |
| Major noncardiac surgery              | Diabetes mellitus                     |
| Nephrotoxic drugs                     | Cancer                                |
| Radiocontrast agents                  | Anemia                                |
| Poisonous plants and animals          |                                       |

CKD, chronic kidney disease; CPB, cardiopulmonary bypass.

# The “modern” approach



AKI in Hospitalized Children: Epidemiology and Clinical Associations in a National Cohort

Scott M. Sutherland,\* Jun Ji,<sup>‡</sup> Farnoosh H. Sheikh,<sup>‡</sup> Eric Widen,<sup>‡</sup> Lu Tian,<sup>‡</sup> Steven R. Alexander,\* and Xuefeng B. Ling<sup>‡</sup>

Table 3. Unadjusted AKI associations

| Patients >1 Mo of Age                      |                                      | Patients ≤1 Mo of Age                                   |                                      |
|--|--------------------------------------|---|--------------------------------------|
| Associated Factor                          | Odds Ratio (95% Confidence Interval) | Associated Factor                                       | Odds Ratio (95% Confidence Interval) |
| Diagnosis category associations            |                                      | Diagnosis category associations                         |                                      |
| Shock                                      | 2.15 (1.95 to 2.36)                  | Condition due to external cause                         | 1.61 (1.39 to 1.87)                  |
| Septicemia                                 | 1.37 (1.32 to 1.43)                  | Severe sepsis   |                                      |
| Liver diseases                             | 1.24 (1.18 to 1.28)                  | Sepsis  |                                      |
| Coagulation/bleeding disorders             | 1.23 (1.18 to 1.28)                  | Liver diseases  | 1.58 (1.32 to 1.89)                  |
| Thrombocytopenia                           |                                      | Circulatory disease                                     | 1.47 (1.32 to 1.65)                  |
| Disseminated intravascular coagulation     |                                      | Complication of surgical care                           | 1.42 (1.24 to 1.63)                  |
| Coagulation defect not otherwise specified |                                      | Bleeding complicating procedure                         |                                      |
| Respiratory failure                        | 1.21 (1.17 to 1.25)                  | Cardiac surgical complication                           |                                      |
| Hypertension                               | 1.2 (1.14 to 1.27)                   | Postoperative infection                                 |                                      |
| Pulmonary collapse/pleurisy                | 1.15 (1.11 to 1.19)                  | Fluid/electrolyte disorders                             | 1.33 (1.25 to 1.42)                  |
| Anemia                                     | 1.1 (1.07 to 1.12)                   | Perinatal conditions not otherwise specified            | 1.2 (1.16 to 1.25)                   |
| Fluid/electrolyte disorders                | 1.09 (1.07 to 1.1)                   | Neonatal arrhythmia                                     |                                      |
| Nutritional/endocrine/metabolic disorders  | 1.05 (1.03 to 1.07)                  | Neonatal dehydration                                    |                                      |
| Disorder phosphorous metabolism            |                                      | Cardiac congenital anomalies                            | 1.18 (1.13 to 1.23)                  |
| Hypocalcemia                               |                                      | Respiratory distress syndrome                           | 1.06 (1.01 to 1.1)                   |
| Disorder of magnesium metabolism           |                                      |   |                                      |
| Condition caused by external cause         | 1.05 (1.02 to 1.07)                  |   |                                      |
| Severe sepsis                              |                                      |   |                                      |
| Sepsis                                     |                                      |   |                                      |
| Hypoxemia                                  |                                      |   |                                      |
| Procedural category associations           |                                      | Procedural category associations                        |                                      |
| Intubation/mechanical ventilation          | 1.2 (1.16 to 1.25)                   | Extracorporeal circulatory support                      | 2.58 (2.04 to 3.26)                  |
| Vascular catheterization                   | 1.18 (1.14 to 1.22)                  | Extracorporeal membrane oxygenation                     |                                      |
| Parenteral/enteral nutrition               | 1.14 (1.09 to 1.19)                  | Extracorporeal membrane oxygenation for cardiac surgery |                                      |
| Blood transfusion                          | 1.11 (1.08 to 1.15)                  | Operating room procedure on vessel                      | 2.07 (1.78 to 2.41)                  |
|  |                                      | Occlusion of thoracic vessel                            |                                      |
|  |                                      | Arterial suture   |                                      |
|  |                                      | Resection of thoracic vessel                            |                                      |
|  |                                      | Blood transfusion                                       | 1.42 (1.32 to 1.53)                  |
|  |                                      | Vascular catheterization                                | 1.16 (1.11 to 1.21)                  |
|  |                                      | Intubation/mechanical ventilation                       | 1.14 (1.1 to 1.18)                   |
|  |                                      | Parenteral/enteral nutrition                            | 1.1 (1.05 to 1.14)                   |

# Electronic Health Record Identification of Nephrotoxin Exposure and Associated Acute Kidney Injury

**TABLE 4** Distribution of High NTMx Exposure Admissions and AKI Rates by Specialty Service

| Services                              | High NTMx Case |                | AKI Cases |     |                | Gender |      |
|---------------------------------------|----------------|----------------|-----------|-----|----------------|--------|------|
|                                       | Count          | % <sup>a</sup> | No        | Yes | % <sup>b</sup> | Female | Male |
| Bone marrow transplant                | 263            | 27.83          | 142       | 121 | 46.01          | 108    | 155  |
| Liver transplant                      | 131            | 13.86          | 84        | 47  | 35.88          | 81     | 50   |
| Oncology                              | 105            | 11.11          | 68        | 37  | 35.24          | 47     | 58   |
| Pulmonary (excluding cystic fibrosis) | 77             | 8.15           | 54        | 23  | 29.87          | 32     | 45   |
| Cystic fibrosis                       | 71             | 7.51           | 65        | 6   | 8.45           | 43     | 28   |
| General pediatrics                    | 64             | 6.77           | 60        | 4   | 6.25           | 35     | 29   |
| Gastrointestinal surgery, trauma      | 39             | 4.13           | 28        | 11  | 28.21          | 19     | 20   |
| Orthopedics                           | 30             | 3.17           | 25        | 5   | 16.67          | 21     | 9    |
| Cardiology                            | 27             | 2.86           | 18        | 9   | 33.33          | 13     | 14   |
| Urology                               | 27             | 2.86           | 25        | 2   | 7.41           | 12     | 15   |
| Neurosurgery                          | 26             | 2.75           | 22        | 4   | 15.38          | 10     | 16   |
| Gastroenterology lumen                | 25             | 2.65           | 18        | 7   | 28.00          | 10     | 15   |
| Otolaryngology                        | 21             | 2.22           | 15        | 6   | 28.57          | 9      | 12   |
| Neurology                             | 20             | 2.12           | 18        | 2   | 10.00          | 9      | 11   |
| Nephrology                            | 11             | 1.16           | 6         | 5   | 45.45          | 4      | 7    |
| Cardiothoracic surgery                | 2              | 0.21           | 2         | 0   | 0.00           | 1      | 1    |
| Ophthalmology                         | 2              | 0.21           | 2         | 0   | 0.00           | 1      | 1    |
| Physical medicine and rehabilitation  | 2              | 0.21           | 2         | 0   | 0.00           | 2      | 0    |
| Rheumatology                          | 2              | 0.21           | 1         | 1   | 50.00          | 2      | 0    |
| Total                                 | 945            |                | 655       | 290 |                | 459    | 486  |

NTMx, nephrotoxic medication.

<sup>a</sup> Represents the percentage of high NTMx cases by each specialty service.

<sup>b</sup> Represents the AKI rates for each specialty service.

NON-AKI

SEPSIS

NEPHROTOXICITY

CATABOLISM

Several simultaneous  
mechanisms →  
Who's the guilty?

SHOCK

CAPILLARY  
LEAK SYNDROME

AKI



NIH Public Access

Author Manuscript

*Compr Physiol.* Author manuscript; available in PMC 2014 February 10.

Published in final edited form as:

*Compr Physiol.* 2012 April ; 2(2): 1303–1353. doi:10.1002/cphy.c110041.

## Pathophysiology of Acute Kidney Injury

David P. Basile<sup>1</sup>, Melissa D. Anderson<sup>2</sup>, and Timothy A. Sutton<sup>2</sup>

<sup>1</sup>Department of Cellular & Integrative Physiology, Indiana University School of Medicine, Indianapolis, IN

<sup>2</sup>Department of Medicine, Division of Nephrology, Indiana University School of Medicine, Indianapolis, IN

- Tubular Damage: 1. Ischemic, 2. Nephrotoxic
- Glomerular Damage : glomerulopathies
- Interstitial Damage: acute interstitial nephritis (antibiotics, infections )
- Vascular Damage: hemolytic uremic syndrome (HUS)/thrombotic thrombocytopenia purpura (TTP)



baseline conditions

hemodynamic disturbances

nephrotoxic insults

inflammatory responses




# *KIDNEY OXYGENATION*

- Even though the kidney is only 0.5% of total bodyweight, it uses approximately 7% of the O<sub>2</sub> consumed by the body
- Under pathological conditions the balance of O<sub>2</sub> supply compared with demand is disturbed due to the unique arrangement of the renal microvasculature and its diffusive shunting pathways

# Microvascular endothelial injury and dysfunction during ischemic acute renal failure

TIMOTHY A. SUTTON, CHARLES J. FISHER, and BRUCE A. MOLITORIS

*Division of Nephrology, Department of Medicine, and the Indiana Center for Biological Microscopy, Indiana University School of Medicine, Indianapolis, Indiana; Abbott Laboratories, Chicago, Illinois; and the Roudebush VA Medical Center, Indianapolis, Indiana, USA*




**Fig. 1. Relationship between the clinical phases and the cellular phases of ischemic acute renal failure (ARF), and the temporal impact on organ function as represented by the glomerular filtration rate (GFR).** Prerenal azotemia exists when a reduction in renal blood flow causes a reduction in GFR. A variety of cellular and vascular adaptations maintain renal epithelial cell integrity during this phase. The initiation phase occurs when a further reduction in renal blood flow results in cellular injury, particularly the renal tubular epithelial cells, and a continued decline in GFR. Vascular and inflammatory processes that contribute to further cell injury and a further decline in GFR usher in the proposed extension phase. During the maintenance phase, GFR reaches a stable nadir as cellular repair processes are initiated in order to maintain and re-establish organ integrity. The recovery phase is marked by a return of normal cell and organ function that results in an improvement in GFR.

## MAIN MECHANISMS OF AKI PHASES

- ***Initiation***: ATP depletion, disruption of cytoskeleton (F-actin damage), up-regulation of IL1, IL6, TNF $\alpha$ ,
- ***Extension***: inflammatory cascade of cytokines
- ***Maintenance***: repair, migration, apoptosis and proliferation
- ***Recovery***: cellular differentiation continues, epithelial polarity is re-established and organ function returns





**Figure 8. The continuum of renal cell damage**

Individual renal tubular cells are likely to respond in different ways to injury depending upon the severity of the noxious stimulus. The majority of cells presumably remain viable, either because they escape injury altogether, or because they are only sublethally injured and able to recover. More severe injury likely results in apoptosis, whereas necrosis only occurs when cells are subjected to extremely severe injury that leads to critical energy depletion and subsequent metabolic collapse. Legend and figure from citation (320).

A




B



**Figure 2. Regional blood flow is altered following injury in ischemic AKI**

Immediately following ischemic injury total renal blood flow is reduced but more striking are the regional deficits in blood flow that exist in the cortex, outer stripe of outer medulla and inner stripe of the outer medulla as indicated in panel A (data from (251)). As overall blood flow starts to recover in the ensuing hours after injury, profound regional alterations in blood flow remain with progressive and **profound reduction of the blood flow to the outer stripe of the outer medulla** as indicated in B (data from (202)).




**Figure 3. Interplay between tubular and vascular injury leading to sustained reductions of GFR in the extension phase of AKI**

Injury induced by ischemia can result in damage to both the tubular as well as the microvascular compartment. Resolution of vasoconstriction appears effective at reducing injury when administered prophylactically, but not following established injury. Resistance may be due to exacerbated inflammation, which may impart reductions in RBF and GFR insensitive to vasodilator therapies. Of central importance in this process is the activation of inflammatory processes which are influenced by factors released by damaged proximal tubules as well as adhesion of damaged microvascular cells. Infiltrating leukocytes may impinge on RBF either by secreting vasoactive factors, or by contributing to the disruption of flow by physical interference. In addition, exacerbated hypoxia leading to tubular obstruction may contribute to reductions in GFR independent of vasodilator therapy. From citation (531)



**Fig. 1** Summary of the pathophysiologic interaction between sepsis and acute kidney injury (AKI). *RRT* Renal replacement therapy



# CONCLUSIONS

- AKI genesis is a challenging process
- AKI causes definition has been and is changing in last years due both to improved recognition (emerging countries) and to changes in AKI exposure mainly as a consequence of new treatments (developed countries)
- AKI genesis constantly depends on and may interact with the genesis of underlying disease
- Better comprehension of AKI genesis mechanisms is a clue issue to its prevention , provided that AKI recognition is made in time.

OSPEDALE DEL BAMBINO GESÙ A ROMA

*Via delle Zoccolatte II. 12*



OFFERTE PER LAVORI NECESSARI ALL'AMPLIAZIONE DELL'OSPEDALE SPECIALE  
PER I BAMBINI





# KIDNEY OXYGENATION

- Renal oxygenation: balance between oxygen ( $O_2$ ) supply and consumption ( $QO_2$ )
- Under physiological steady state conditions ,  $O_2$  supply to the renal tissues is well in excess of the  $O_2$  demand :
- Renal  $O_2$  extraction in the healthy kidney is only 10–15% (in most other organs it is closer to 45%)
- Under pathological conditions the balance of  $O_2$  supply compared with demand is disturbed due to the unique arrangement of the renal microvasculature and its diffusive shunting pathways
- High  $O_2$  demand is associated with the tubular  $QO_2$  necessary for solute exchange and the high rate of aerobic glycolysis
- Even though the kidney is only 0.5% of total bodyweight, it uses approximately 7% of the  $O_2$  consumed by the body
- The vast majority of  $QO_2$  is due to reabsorption of approximately 99.5% of filtered sodium ( $Na^+$ )

# Causes

- **AKI due to other causes >>> primary renal disease**
  - Developing countries:
    - More importance of primary renal disease, Malaria, HUS
    - However, now secondary causes emerging
  - “TOP HITS” around room:
    - “ATN”
    - “Hypovolemia”
    - Sepsis
    - Nephrotoxic medication – almost always significant when looked at!!
    - Heme-Onc
    - Cardiac surgery

# Dialysis Unit, “Bambino Gesù” Pediatric Hospital Roma, Italy.




*Doctor:*  
S. Picca

*Headnurse:*  
V. Bandinu

*Nurses:*  
N. Avari  
D. Ciullo  
E. Iacoella  
P. Iovine  
P. Lozzi  
L. Stefani

*Nurse Coordinator:*  
M. D'Agostino

[stefano.picca@opbg.net](mailto:stefano.picca@opbg.net)



## Table 5 | Causes of AKI and diagnostic tests

Selected causes of AKI requiring immediate diagnosis and specific therapies

Recommended diagnostic tests

Decreased kidney perfusion

Volume status and urinary diagnostic indices

Acute glomerulonephritis, vasculitis, interstitial nephritis, thrombotic microangiopathy

Urine sediment examination, serologic testing and hematologic testing

Urinary tract obstruction

Kidney ultrasound

AKI, acute kidney injury.



# *CHANGE IN THE EPIDEMIOLOGY OF AKI*

**Single organ failure**

**Primary renal disease**

+

**MODS**


**AKI as complication  
of  
systemic diseases**

**Renal ward/  
Dialysis Unit**



**ICU**

## *AKI Incidence: PICU*




# IN NEONATES

**“Immature” newborn kidney**

**Low GFR**

**High Urine Output**



To accomplish the physiologic extracellular post-natal fluid reduction (10% weight loss)

To manage the large water load coming from breast feeding

# nRIFLE

**Table 1. Synoptic view of adult, paediatric and neonatal RIFLE**

|  | Creatinine criteria  |  |               | Urine output criteria                                       |  |  |
|--|--|--|---------------|---|--|--|
|  | <i>RIFLE</i>   | <i>pRIFLE</i>  | <i>nRIFLE</i> | <i>RIFLE</i>  | <i>pRIFLE</i>                                  | <i>nRIFLE</i>                                  |
| Risk   | Increased creatinine $\times 1.5$ or GFR decreases $>25\%$   | eCCL decrease by 25%   | ?             | UO $\leq 0.5$ mL/kg/h $\times 6$ h                          | UO $< 0.5$ mL/kg/h for 8 h                     | UO $< 1.5$ mL/kg/h for 24 h                    |
| Injury   | Increased creatinine $\times 2$ or GFR decreases $>50\%$   | eCCL decrease by 50%   | ?             | UO $\leq 0.5$ mL/kg/h $\times 12$ h                         | UO $< 0.5$ mL/kg/h for 16 h                    | UO $< 1.0$ mL/kg/h for 24 h                    |
| Failure  | Increased creatinine $\times 3$ or GFR decreases $>75\%$ or creatinine $\geq 4$ mg/dL (acute rise of $\geq 4$ mg/dL) | eCCL decrease by 75% or eCCL $< 35$ mL/min/1.73 m <sup>2</sup> | ?             | UO $\leq 0.3$ mL/kg/h $\times 24$ h or anuria $\times 12$ h | UO $< 0.3$ mL/kg/h for 24 h or anuric for 12 h | UO $< 0.7$ mL/kg/h for 24 h or anuric for 12 h |
| Loss   | Persistent failure $>4$ weeks  |  |               |   |  |  |
| End stage  | Persistent failure $>3$ months   |  |               |   |  |  |
| Question mark ('?') is intended to mean uncertain thresholds.<br>GFR, glomerular filtration rate; Ecl, estimated creatinine clearance; UO, urine output. |  |  |               |   |  |  |

# DISEASE AND SURVIVAL

| Diagnosis | N  | Survival | Diagnosis | N  | %Survival |
|-----------|----|----------|-----------|----|-----------|
| BMT       | 26 | 42%      | HUS       | 16 | 94%       |
| TLS/Malig | 17 | 58%      | ATN       | 46 | 67%       |
| CHD       | 47 | 39%      | Liver Tx  | 22 | 17%       |
| Heart Tx  | 13 | 67%      | Sepsis    | 39 | 33%       |

- Pts on Vasopressors survival = 35%
- Pts not on Vasopressors survival = 89%  
( $p < 0.01$ )

Bunchman TE et al: Ped Neph 16:1067-1071, 2001  
Slide courtesy of T.E.B.